Forbes J M & Co. LLP Buys 3,186 Shares of Eli Lilly and Company $LLY

Forbes J M & Co. LLP raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 37.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 11,714 shares of the company’s stock after acquiring an additional 3,186 shares during the period. Forbes J M & Co. LLP’s holdings in Eli Lilly and Company were worth $8,938,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Laurel Wealth Advisors LLC grew its stake in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Norges Bank bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $8,827,714,000. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after acquiring an additional 765,010 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Eli Lilly and Company by 13.4% during the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after acquiring an additional 564,736 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 3.8%

Eli Lilly and Company stock opened at $1,032.51 on Friday. The firm has a market cap of $976.11 billion, a price-to-earnings ratio of 50.51, a PEG ratio of 0.78 and a beta of 0.35. The stock has a fifty day simple moving average of $1,049.04 and a two-hundred day simple moving average of $868.38. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the company posted $1.18 earnings per share. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analysts Set New Price Targets

LLY has been the subject of a number of analyst reports. National Bankshares set a $1,286.00 target price on shares of Eli Lilly and Company in a research note on Monday, December 1st. Berenberg Bank raised their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research report on Tuesday, December 2nd. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Morgan Stanley increased their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Finally, CICC Research raised their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Five equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Buy” and a consensus price target of $1,174.70.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Nvidia announced a major AI drug‑discovery collaboration with a reported $1 billion lab investment, reinforcing long‑term R&D acceleration and partnership value for Lilly. Nvidia And Eli Lilly To Build $1 Billion AI-Powered Drug Discovery Lab
• Positive Sentiment: Jefferies reaffirmed a Buy and set a $1,300 price target; other street notes (BMO, TipRanks coverage) continue to emphasize Lilly’s leadership in incretin/GLP‑1 franchises and multitherapy growth. This supports medium‑term upside expectations. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Positive Sentiment: J.P. Morgan notes obesity remains front‑and‑center and reported Q4 sales beats, highlighting Lp(a) cardiovascular drugs as an additional growth lever beyond weight‑loss therapies. These messages bolster earnings durability. JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats
• Positive Sentiment: Analysts and sell‑side notes (Zacks) point to continued strong demand for Mounjaro and Zepbound, with improving supply and global uptake offsetting pricing pressure — a near‑term revenue tailwind. How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
• Neutral Sentiment: Mixed media/opinion pieces debate valuation after a strong 2025 gain; some argue to trim exposure while many funds still list Lilly as a long‑term growth holding — suggests investor positioning remains contested. Eli Lilly: Sell It And Buy Novo Nordisk Instead
• Negative Sentiment: A compounding pharmacy sued Lilly and Novo Nordisk in Texas alleging coordinated conduct to limit access to GLP‑1s, raising legal and reputational risk that could pressure pricing/access; markets treat litigation risk as a near‑term negative. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy
• Negative Sentiment: The FDA reportedly delayed a decision on Lilly’s oral obesity pill orforglipron (and other priority voucher awardees), a regulatory setback that catalyzed intraday selling as it defers potential market expansion vs. peers. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.